Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) (REDUCE-MRSA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00980980 |
Recruitment Status
:
Completed
First Posted
: September 21, 2009
Results First Posted
: July 30, 2014
Last Update Posted
: May 2, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type: | Interventional |
---|---|
Study Design: | Allocation: Randomized; Primary Purpose: Prevention |
Condition: |
Methicillin-resistant Staphylococcus Aureus |
Intervention: |
Drug: Chlorhexidine bath and nasal mupirocin |

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
---|
45 out of 165 Hospital Corporation of America (HCA) hospitals were recruited for this trial of adult ICUs. There was a 12-month baseline period from January 1 through December 31, 2009; a phase-in period from January 1 through April 7, 2010; and an 18-month intervention period from April 8, 2010 through September 30, 2011. |
Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
---|
74,256 patients were involved in the intervention period among adult ICUs from the 43 participating hospitals. Routinely collected information for about 48,390 individuals cared for during the baseline period was used for comparison to the experience of the patients in all three arms of the Intervention period. |
Reporting Groups
Description | |
---|---|
Arm 1: Usual Care-Active Surveillance | Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+ |
Arm 2: Targeted Decolonization |
Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+ Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) |
Arm 3: Universal Decolonization |
Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance , Contact Precautions for MRSA+ Chlorhexidine bath and nasal mupirocin: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US – a combination of daily baths with 2% chlorhexidine cloths plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) |
Participant Flow: Overall Study
Arm 1: Usual Care-Active Surveillance | Arm 2: Targeted Decolonization | Arm 3: Universal Decolonization | |
---|---|---|---|
STARTED | 16 | 14 | 13 |
COMPLETED | 16 | 13 | 13 |
NOT COMPLETED | 0 | 1 | 0 |
Withdrawal by Hospital | 0 | 1 | 0 |

1. Primary: | Main Outcome: Patients With Nosocomial MRSA Clinical Cultures [ Time Frame: The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge. ] |
2. Secondary: | MRSA Bloodstream Infection [ Time Frame: The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge. ] |
3. Secondary: | ICU-attributable All-pathogen Bloodstream Infection [ Time Frame: The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge. ] |
4. Secondary: | Intervention Impact on Healthcare Costs [ Time Frame: 12-month period ] |
5. Secondary: | Blood Culture Contamination Rates [ Time Frame: 24-month time frame for this analysis represents a 6-month baseline and 18-month intervention period. ] |
6. Secondary: | Intervention Impact on Bacteriuria and Candiduria [ Time Frame: 30-month time frame represents 12-month baseline and 18-month intervention periods. ] |
7. Secondary: | Intervention Impact on Mupirocin Susceptibility of MRSA Isolates [ Time Frame: 25-month time frame represents 7-month baseline and 18-month intervention periods ] |
8. Secondary: | Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates [ Time Frame: 25-month time frame represents 7-month baseline and 18-month intervention periods ] |

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
---|
No text entered. |

Principal Investigators are NOT employed by the organization sponsoring the study. |
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
Results Point of Contact:
Organization: University of California, Irvine
phone: 949-824-5073
e-mail: sshuang@uci.edu
Publications of Results:
Other Publications:
Responsible Party: | Richard Platt, Harvard Pilgrim Health Care |
ClinicalTrials.gov Identifier: | NCT00980980 History of Changes |
Other Study ID Numbers: |
PH000223K HHSA2902005003I TO #11 |
First Submitted: | September 19, 2009 |
First Posted: | September 21, 2009 |
Results First Submitted: | May 14, 2014 |
Results First Posted: | July 30, 2014 |
Last Update Posted: | May 2, 2017 |